Abstract Details

Title Anti-CGRP Monoclonal Antibodies for Neuropathic Pain in Patients with Migraine Headache

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) Neuromuscular and Clinical Neurophysiology (EMG) Posters (7:00 AM-5:00 PM)

Poster/Presentation
Number 072

Objective The aim of this study was to assess the effectiveness of anti-CGRP monoclonal antibodies for neuropathic pain in patients with coexisting chronic migraine.

Background Besides its contribution to pain transmission in migraines, there is some evidence that calcitonin gene-related peptide (CGRP) may also play a role in peripheral neuropathy and neuropathic pain, though this has not been explored.

Design/Methods A retrospective chart review was conducted of 14 patients who were administered anti-CGRP monoclonal antibodies with a diagnosis of both chronic migraine and peripheral neuropathy with neuropathic pain. We collected data on demographics, clinical features, medications taken for neuropathy, and patient-reported scores on the neuropathy pain scale (NPS) and frequency of migraine headache days (MHDs) per month. NPS scores ranged 0-100. Data were collected 3 months before treatment, at baseline, and 3, 6, 9, and 12 months after treatment.

Results The patients included in this study were an average age of 48.5 years (range 38-60). Diabetes was the cause of neuropathy in 6 patients (43%), trisulfated heparin disaccharide (TS-HDS) was the cause in 2 patients (14%), alcohol was the cause in 1 patient (7%), and the cause of neuropathy was idiopathic in 5 patients (36%). Patients observed a 41.7% decrease in NPS scores from 89.3 at baseline to 52.1 at 12 months post-treatment (p<0.05). Additionally, there was a 33.3% decrease in MHDs per month from 19.8 at baseline to 13.2 at 12 months post-treatment (p<0.05).

Conclusions The administration of anti-CGRP monoclonal antibodies improved neuropathic pain in patients who also had chronic migraine.

Authors/Disclosures
Seung Ah Kang PRESENTER	Seung Ah Kang has nothing to disclose.
Raghav Govindarajan, MD, F�鶹��ýӳ�� (HSHS St. Elizabeth Medical Group)	Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.

�鶹��ýӳ��

�鶹��ýӳ��